---
schema_version: "secwatch.filing_event.v1"
accession: "0001398733-26-000033"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2026-06-10T20:02:32+00:00"
generated_at: "2026-06-10T20:03:09.262345+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Aquestive Therapeutics shareholders elect three Class II directors at 2026 annual meeting

## Summary
- Gregory B. Brown, M.D. elected with 41,373,033 votes for; 1,222,711 against.
- John S. Cochran elected with 36,914,899 votes for; 5,680,845 against.
- Abigail L. Jenkins elected with 39,094,166 votes for; 3,501,578 against.
- Advisory say-on-pay proposal passed: 37,798,609 for, 3,192,381 against.
- KPMG LLP ratified as independent auditor for FY 2026 with 78,804,323 votes for.

## SEC filing metadata
- accession: 0001398733-26-000033
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2026-06-10T20:02:32+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000033/0001398733-26-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000033/aqst-20260610.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001398733-26-000033
- JSON: https://secwatch.observer/filing/0001398733-26-000033.json
- Plain text: https://secwatch.observer/filing/0001398733-26-000033.txt

## Key facts
- Shareholder Votes
  Aquestive Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm at the 2026-06-10 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified. Votes For Votes Against Votes Abstaining 78,804,323 910,690 346,313
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000033/0001398733-26-000033-index.htm
- Shareholder Votes
  Aquestive Therapeutics, Inc. shareholders approved Advisory vote to approve executive compensation at the 2026-06-10 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year. Votes For Votes Against Votes Abstaining Broker Non-Votes 37,798,609 3,192,381 1,604,754 37,465,582
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000033/0001398733-26-000033-index.htm
- Shareholder Votes
  Aquestive Therapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: The following director nominees were elected to serve as Class II members of the Board of Directors, to serve for a three-year term until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Nominee Votes For Votes Against Votes Abstaining Broker Non-Votes Gregory B. Brown, M.D. 41,373,033 — 1,222,711 37,465,582 John S. Cochran 36,914,899 — 5,680,845 Abigail L. Jenkins 39,094,166 — 3,501,578
  evidence_url: https://www.sec.gov/Archives/edgar/data/1398733/000139873326000033/0001398733-26-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.